Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial
Authors
John A. Todd (ORCID: https://orcid.org/0000-0003-2740-8148)
An Jacobs (ORCID: https://orcid.org/0000-0003-2556-4454)
Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial
John A. Todd, An Jacobs, Mariusz Ołtarzewski, Kristina Casteels et al.
Citations
1 citations
Journal
The Lancet
Topics
Diabetes and associated disorders
Field-Weighted Citation Impact (FWCI)
1.82
article
Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial
John A. Todd, An Jacobs, Mariusz Ołtarzewski, Kristina Casteels, Olga Kordonouri, Christiane Winkler, Ezio E. Bonifacio, Peter Achenbach, Reinhard Berner, Matthew D. Snape, Thekla von dem Berge, Florian Haupt, Manu Vatish, Anette‐Gabriele Ziegler, Andreas Weiß, Helena Elding Larsson, Markus Pfirrmann, Agnieszka Szypowska, Markus Lundgren, Angela Hommel
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
The LancetVol. 406(10519)
Institutions
Medical University of Warsaw (PL), Universitair Ziekenhuis Leuven (BE), John Radcliffe Hospital (GB), Helmholtz Zentrum München (DE), University of Oxford (GB), Kinderkrankenhaus auf der Bult (DE), Zimmer Biomet (Germany) (DE), Skåne University Hospital (SE), Oxford BioMedica (United Kingdom) (GB), Deutsches Diabetes-Zentrum e.V. (DE), German Center for Diabetes Research (DE), University Hospital Carl Gustav Carus (DE), Paul Langerhans Institute Dresden (DE), Heinrich Heine University Düsseldorf (DE), Technische Universität Dresden (DE), Ludwig-Maximilians-Universität München (DE), KU Leuven (BE)
Funders
Eli Lilly and Company, Leona M. and Harry B. Helmsley Charitable Trust, Universität Basel, Integrated BioBank of Luxembourg, Imperial College London, University of Oxford, University of Bristol, Bundesministerium für Bildung und Forschung, Technische Universität München, Novo Nordisk Fonden